Nyrada
Menu
NYR:
Market Cap*:
Price Delay ~20min
Home
About Us
Company Overview
Board of Directors
Management
Scientific Advisory Board
Corporate Governance
Our Science
Lead Drug Development
Brain Injury Program
Cholesterol Lowering Program
Technical Glossary
Drug Development Pathway
Investors
Investor Welcome
ASX Announcements
Brain Injury Program
Cholesterol-Lowering Program
Financial Reports
Corporate Announcements
Investor Presentations
Share Price Information
Key Dates
Investors Glossary
Annual Reports
Analyst Reports
Annual General Meeting
Extraordinary General Meeting
Past Shareholder Meetings
News & Insights
Presentations & Interviews
Media
Newsletters
Publications
Contact Us
Contact Us
Working at Nyrada
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Welcome
ASX Announcements
Brain Injury Program
Cholesterol-Lowering Program
Financial Reports
Corporate Announcements
Investor Presentations
Share Price Information
Key Dates
Investors Glossary
Annual Reports
Analyst Reports
Annual General Meeting
Extraordinary General Meeting
Past Shareholder Meetings
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
28-Feb-2024
Nyrada CEO James Bonner interview with 180 Markets
28-Feb-2024
Significant Neuroprotection in NYR Preclinical Brain Injury
20-Feb-2024
Nyrada Half Year Results FY2024
20-Feb-2024
Appendix 4D and Half Year Report to 31 December 2023
19-Jan-2024
Amended and Restated Certificate of Incorporation and Bylaws
17-Jan-2024
Quarterly Activities Report and Appendix 4C
8-Dec-2023
Nyrada Receives A$3.54M R&D Tax Incentive Rebate
20-Nov-2023
Nyrada Annual General Meeting Results
20-Nov-2023
Nyrada AGM 2023 CEO Presentation
20-Nov-2023
Nyrada AGM 2023 Chair Address
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
Next